Acumen Pharmaceuticals (ABOS) has released an update to notify the public and investors about its officers.
Acumen Pharmaceuticals, Inc. has appointed James Doherty as its President and Chief Development Officer, effective February 1, 2024, coinciding with Daniel O’Connell assuming the role of Chief Executive Officer. Doherty brings extensive experience from Sage Therapeutics, where he served in various capacities, most recently as Chief Development Officer, and has a strong background in neuroscience research with prior leadership roles at AstraZeneca. He holds a B.A. in Biology and a Ph.D. in Neurobiology and has no familial ties or material interests with the company’s executives or directors.
For further insights into ABOS corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.
